USE OF ETANERCEPT IN JUVENILLE ANKYLOSING SPONDILLO-ARTHRITIS WITH EARLY ONSET
https://doi.org/10.15690/vsp.v11i2.233
Abstract
A history case of juvenile ankylosing spondillo-arthritis onset with rapid development of asymmetric poliarticular involvement, sacroileitis, patient’s disabling and his and his family disabling is represented in this article. The activity of disease was arrested by usage of soluble TNF receptors — etanercept. The function of involved joints was completely restored, the boy’s life quality significantly improved. Inactive stage of disease was documented in 4 weeks, remission stage — in 7 months after the beginning of treatment.
About the Authors
A. N. Fetisova
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Russian Federation
E. I. Alexeeva
Scientific Centre of Children Health RAMS, Moscow
I.M. Sechenov First Moscow State Medical University
Russian Federation
Ekaterina Iosifovna Alexeeva, PhD, professor, Head of the Pediatric Department of I.M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH of RAMS
Russian Federation
Ekaterina Iosifovna Alexeeva, PhD, professor, Head of the Pediatric Department of I.M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH of RAMS
T. M. Bzarova
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Russian Federation
N. I. Taybulatov
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Russian Federation
A. V. Starikova
The Helmholtz Moscow Research Institute of Eye Diseases
Russian Federation
Russian Federation
A. V. Anikin
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Russian Federation
G. A. Bekdzhanyan
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Russian Federation
References
1. Cassidy J. T., Petty R. E., Laxer R. M. et al. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier. 2010. 794 p.
2. Nikishina I. P. Consilium medicum — Consilium medicum. 2006; 8 (2): 20–23.
3. Pepmueller P. H., Moore T. L. Juvenile onset spondylo arthropathies. Curr. Opin. Rheumatol. 2000; 12: 269–273.
4. Prier A. M. Spondyloarthropathies in childhood. Bailiere`s Clin. Rheumatol. 1998; 12: 287–307.
5. Burgos-Vargas R., Pacheco-Tena C., Vazquez-Mellado J. Juvenileonset spondyloarthropathies. Rheum. Dis. Clin. North. Am. 1997; 23: 569–598.
6. Nikishina I. P. Yuvenil'nyi ankiloziruyushchii spondiloartrit. Prakticheskoe rukovodstvo po detskim boleznyam. Tom III. Pod obshchei red. V. F. Kokolinoi, A. G. Rumyantseva [Juvenile Ankylosing Spondylitis. Manual on Child Diseases. Volume 3. Edited by V. F. Kokolina, A. G. Rumyantsev]. Moscow, Medpraktika, 2004. pp. 620–649.
7. Kuz'mina N. N. Yuvenil'nyi ankiloziruyushchii spondiloartrit. Detskaya revmatologiya. Rukovodstvo dlya vrachei. Pod red. A. A. Baranova, L. K. Bazhenovoi [Juvenile Ankylosing Spondylitis. Pediatric Rheumatology. Guideline. Edited by A. A. Baranov, L. K. Bazhenova]. Moscow, Meditsina, 2002. pp. 141–182.
8. Loginova E.Yu. Yuvenil'nyi artrit vo vzrosloi revmatologicheskoi klinike: kliniko-funktsional'naya kharakteristika i iskhody. Avtoref. dis. … kand. med. nauk [Juvenile Arthritis in Adult Rheumatologic Clinical Picture: Clinical and Functional Characteristics, Fate. Author’s abstract]. Moscow, 2001.
9. Bowyer S., Roettcher P. and the members of the Pediatric Rheumatology Database Research Group. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. J. Rheumatol. 1996; 23: 1968–1974.
10. Towner S. R., Michet C. J. Jr, O’Fallon W. M., Nelson A. M. The epidemiology of juvenile arthritis in Rochester, Minnesota 1960– 1979. Arthritis Rheum. 1983; 26: 1208–1213.
11. Andersson Gare B. Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. Clin. Exp. Rheumatol. 1999; 17: 367–374.
12. Manners P. J., Bower C. Worldwide prevalence of juvenile arthritis: why does it vary so much? J. Rheumatol. 2002; 29: 1520–1530.
13. Bochkova A. G. Consilium medicum — Consilium medicum. 2006; 8 (2).
14. Fearon U., Veale D. J. Pathogenesis of psoriatic arthritis. Clin. Exp. Dermatol. 2001; 26: 333–337.
15. Kalden J. R. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res. 2002; 4 (Suppl. 2): 534–540.
16. Mease P., Kivitz A. J., Burch F. X. et al. Etanercept treatment of psoriatic arthritis: sarety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264–2272.
17. Beutler B. A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.
18. Granfors K., Marker-Hermann E., De Kayser F. The cutting edge of spondiloarthropathy research in the millennium. Arthritis Rheum. 2002; 46 (3): 606–613.
19. Mease P., Antoni C. E. Psoriatic arthritis treatment: biological response modifiers. Ann. Rheum. Dis. 2005; 64 (Suppl. 2): 78–82.
20. Badokin V. C. Vrach — Physician. 2005; 5: 48–52.
21. Reed M. R., Taylor A. L. Tumor necrosis factor inhibitors in ankylosing spondylitis. Intern. Med. J. 2008; 38 (10): 781–789.
22. Haibel H., Song I. H., Rudwaleit M. et al. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 week in daily practice. Clin. Exp. Rheumatol. 2008; 26 (2): 247–252.
23. Braun J., Deodhar A., Dijkmans B. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008; 59 (9): 1270–1278.
24. Griffoul I., Giraudeau B., Mulleman D. et al. Infliximab for treating axial spondylarthropathy in everyday practice. Joint Bone Spine. 2009; 76 (1): 39–43.
25. Rumyantseva O. A. Nauchno-prakticheskaya revmatologiya — Reseach and practical rheumatology. 2006; 4: 11–19.
26. Kozlova A. L., Alekseeva E. I., Valieva S.I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 8 (2): 20–26.
27. Alekseeva E. I., Kozlova A. L., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2010; 9 (2): 23–31.
28. Alekseeva E. I., Alekseeva A. M., Valieva S. I. etc. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (2): 42–54.
29. Alekseeva E. I., Valieva S. I., Denisova R. V. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (5): 51–57.
30. Moreland L. W., Schiff M. H., Baumgarthner S. W. et al. Etanercept therapy in rheumatoid arthritis. Ann. Int. Med. 1999; 130: 478–486.
31. Moreland L. W., Scott M. D., Baumgarther W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997; 337: 141–147.
32. Prince F. H., Twilt M., Ten Cate R. et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann. Rheum. Dis. 2008; 68 (5): 635–641.
33. Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann. Rheum. Dis. 2008; 68 (4): 519–525.
34. Nielsen S., Ruperto N., Gerloni V. et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2008; 26 (4): 688–692.
35. Lovell D. J., Reiff A., Ilowite N. T. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58 (5): 1496–1504.
36. Robinson R. F., Nahata M. C., Hayes J. R. et al. Quality-of-Life Measurements in Juvenile Rheumatoid Arthritis Patients Treated with Etanercept. Clin. Drug. Investig. 2003; 23 (8): 511–518.
37. Palazzi C., D’Angelo S., Cantini F. et al. Etanercept in spondylo arthropathies. Part I: current evidence of efficacy. Clin. Exp. Rheumatol. 2011; 29 (5): 858–64.
38. Navarro-Sarabia F., Fernandez-Sueiro J. L., Torre-Alonso J. C., Grata cos J. et al. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford). 2011; 50 (10): 1828–37.
39. Braun J., van der Horst-Bruinsma I. E., Huang F., BurgosVargas R. et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011; 63 (6): 1543–51.
Review
For citations:
Fetisova A.N., Alexeeva E.I., Bzarova T.M., Taybulatov N.I., Starikova A.V., Anikin A.V., Bekdzhanyan G.A. USE OF ETANERCEPT IN JUVENILLE ANKYLOSING SPONDILLO-ARTHRITIS WITH EARLY ONSET. Current Pediatrics. 2012;11(2):169-175. (In Russ.) https://doi.org/10.15690/vsp.v11i2.233
Views:
837
Email this article 
